• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    3/3/25 4:05:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADMA alert in real time by email

    FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase

    FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit

    FY 2024 Adjusted EBITDA(1) of $164.6 Million, a 309% YoY Increase

    FY 2024 Adjusted Net Income(2) of $119.2 Million, Compared to $0.7 Million in FY 2023, a 16,810% YoY Increase

    YE 2024 Total Cash Grew to More than $103 Million, Including $60 Million of Debt Organically Discharged During 2H 2024

    High-Titer Plasma Supply Contracts Expected to Provide Foundation for Durable ASCENIV Revenue Growth Through Late 2030s

    FDA Approval of Yield Enhancement Production Process Anticipated by Mid-2025

    FY 2025 and 2026 Total Revenue Guidance Increased to More than $490 Million and $605 Million, Respectively

    FY 2025 and 2026 Adjusted Net Income Guidance Increased to More Than $175 Million and $235 Million, Respectively

    FY 2025 and 2026 Adjusted EBITDA Guidance Increased to More Than $225 Million and $305 Million, Respectively

    ADMA Anticipates Generating Greater Than $1 Billion in Total Annual Revenue Prior to 2030, More Than Doubling the Current 2025 Revenue Forecast

    RAMSEY, N.J. and BOCA RATON, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its fourth quarter and full year 2024 financial results and provided a business update.

    "ADMA delivered exceptional operating and financial results in 2024, with total revenues and Adjusted EBITDA growing 65% and 309% year-over-year, respectively. These results reflect our commitment to operational and financial excellence, as well as the meaningful impact our therapies continue to have on immunocompromised patients," said Adam Grossman, President and Chief Executive Officer of ADMA. "We believe our recently secured long-term high-titer plasma supply agreements mark a transformative milestone, as they significantly expanded our plasma sourcing capacity and are expected to further de-risk both our near-term and long-term growth trajectories. Coupled with record internal high-titer plasma collections, these third-party agreements should provide the critical supply foundation to support our continued commercial expansion. These benefits are anticipated to be favorably compounded with the potential mid-2025 regulatory approval of our enhanced yield production process, which would provide for approximately 20% more finished IG from the same starting plasma."

    Mr. Grossman concluded, "Looking ahead, these strengthened supply commitments are expected to position us to scale new ASCENIV patient starts, deepen penetration into the complex and refractive PI target market, and advance our R&D pipeline with confidence. We believe our strong balance sheet, growing net cash position, and robust intellectual property estate provides a solid foundation for long-term value creation. With a durable and diversified plasma supply, proprietary innovation, and a steadfast commitment to patient care, we are confident in our ability to drive sustained success, accelerating revenue and earnings growth while maintaining an uninterrupted drug supply for those who rely on our biologic therapies."

    Financial Guidance:

    • FY 2025 and 2026 total revenue increased to more than $490 million and $605 million, respectively
    • FY 2025 and 2026 Adjusted Net Income increased to more than $175 million and $235 million, respectively
    • FY 2025 and 2026 Adjusted EBITDA increased to more than $225 million and $305 million, respectively
    • Greater than $1 billion of total annual revenue expected to be achieved prior to 2030, with anticipated outsized earnings growth from current margin levels

    Recent Business Updates & 2025 Objectives:

    • Record ASCENIV demand. Across all forward-looking demand metrics, ASCENIV trends continue to drive record highs into 2025 and, as a result, the Company expects ASCENIV's total revenue share to expand throughout 2025 and beyond. As ASCENIV's benefit in real-world patient outcomes continues and long-term high-titer plasma supply contracts ramp up, ADMA anticipates accelerating ASCENIV's new patient starts and penetration in existing institutions, which would significantly expand its peak revenue potential beyond current levels.



    • Anticipated mid-2025 regulatory approval of innovative yield enhancement production process. Following the year-end 2024 Prior Approval Supplement submission to the U.S. Food and Drug Administration (FDA), ongoing FDA interactions reinforce our confidence in timely potential approval by mid-year 2025. If approved, ADMA anticipates potential revenue and earnings accretion in the second half of 2025. This innovative process has demonstrated an ability to increase production yields by approximately 20% from the same starting plasma volume, potentially driving significant increases to the current financial guidance.



    • Executed high-titer plasma supply contracts on a long-term basis. ADMA's recently executed third-party, high-titer plasma supply contracts are expected to significantly increase access to raw material plasma used to produce ASCENIV. These long-term agreements allow the Company to source high-titer plasma from approximately 250 collection centers, a 5-fold increase in total collection capacity. To date, the pace of procurement from these new contracts has been encouraging and, coupled with ADMA's record internal plasma collections, we believe the Company is well-positioned to meet its revenue targets and potentially achieve greater than $1 billion in total annual revenue prior to 2030, with additional potential growth opportunities thereafter.



    • Strengthened balance sheet and optimizing cost of capital. ADMA generated approximately $48 million in operating cash flow in the fourth quarter of 2024, increasing year-end cash on hand to over $103 million. With this robust cash flow, and the $60 million in debt organically discharged during the second half of 2024, ADMA now holds a net cash surplus relative to the $75 million of total outstanding debt with Ares Capital. The Company anticipates further balance sheet improvements in 2025, driven by projected Adjusted EBITDA growth, sustained cash generation, and continued optimization of its capital structure.



    • Leveraging robust IP estate and innovative R&D engine. ADMA anticipates generating initial animal data for its lead R&D pipeline program, SG-001, targeting S. pneumonia. If approved, SG-001 represents potential upside to the current financial guidance, and ADMA believes the product has the potential to generate $300-500 million or more in high margin annual revenue, with IP protection through at least 2037.



    • Unique asset durability and terminal value. ASCENIV's robust intellectual property estate, covering proprietary plasma screening assays, unique plasma pooling, and methods of immunoglobulin (IG) use, secures brand protection through at least 2035, with potential IP extensions beyond 2035. The Company is confident that regulatory barriers and proprietary know-how further safeguard ASCENIV's branded growth, potentially well beyond 2035. This comprehensive IP portfolio, encompassing IG treatment for all viral-induced respiratory infections, supports ADMA's expectation that ASCENIV is well-positioned to deliver long-term branded growth. We believe ASCENIV may generate one of the most durable earnings streams in the sector.



    Form 10-K Filing Timing. The successful consolidation and reporting of ADMA's financial results is an important milestone for the Company as ADMA's financial profile continues to rapidly grow and improve. KPMG LLP ("KPMG") was engaged by ADMA as the Company's new independent registered public accounting firm in the fourth quarter of 2024. ADMA intends to file a Notification of Late Filing on Form 12b-25 ("Form 12b-25") with the U.S. Securities and Exchange Commission (SEC) to disclose that ADMA expects to file its Annual Report on Form 10-K for the year ended December 31, 2024 ("Form 10-K") within the 15-day extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934 (the "Exchange Act") (i.e., on or before March 18, 2025). The delay in the filing of the Form 10-K is due to a combination of factors relating to the Company's need for additional time to test and document the Company's controls associated with its use of and reliance upon certain third-party service providers and to complete its assessment of the effectiveness of internal control over financial reporting as of December 31, 2024. As a result of the foregoing, KPMG has not yet completed its audit procedures.

    Fourth Quarter 2024 Financial Results:

    Total revenue was $117.5 million for the quarter ended December 31, 2024, as compared to $73.9 million for the quarter ended December 31, 2023, an increase of $43.6 million, or 59%. The increase is primarily related to increased sales of our immunoglobulin products, partially offset by a planned decrease in sales of plasma to third parties due to the increasing retention of plasma for internal intravenous immune globulin (IVIG) production.

    Gross profit was $63.3 million for the quarter ended December 31, 2024, as compared to $31.1 million for the prior year, which represents a gross margin for the fourth quarter 2024 of 54.0%, as compared to 42.1% for the fourth quarter 2023. The improvement in gross margin is primarily driven by a significantly more favorable mix of higher margin IG sales in 2024 as compared to 2023, along with the reduction in other manufacturing costs.

    GAAP Net Income was $111.9 million for the quarter ended December 31, 2024, compared to a net loss of $17.6 million for the quarter ended December 31, 2023. The increase was primarily due to the increase in operating income, lower interest expense, a reduced loss on the extinguishment of debt and the income tax benefit.   

    Adjusted EBITDA was $48.3 million for the quarter ended December 31, 2024, as compared to Adjusted EBITDA of $18.6 million for the quarter ended December 31, 2023. Adjusted EBITDA for the quarter includes all non-GAAP reconciliation items, including stock-based compensation, depreciation, amortization, interest expense and loss on debt extinguishment.

    Adjusted Net Income was $33.4 million for the quarter ended December 31, 2024, as compared to an Adjusted Net Income of $8.5 million for the quarter ended December 31, 2023.

    Full Year 2024 Financial Results:

    Total revenue was $426.5 million for the year ended December 31, 2024, as compared to $258.2 million for the year ended December 31, 2023, an increase of $168.2 million, or 65%. This increase is primarily related to increased sales of ASCENIV, as we continue to experience increased physician, payer and patient acceptance and utilization of this product.

    Gross profit was $219.6 million for the year ended December 31, 2024, as compared to $88.9 million for the prior year, which represents a gross margin for fiscal 2024 of 51.5%, as compared to 34.4% for fiscal 2023. The improvement in gross margin is primarily driven by a significantly more favorable mix of higher margin IG sales in 2024 as compared to 2023, along with the reduction in other manufacturing costs as well as efficiencies in our operations.

    GAAP net income was $197.7 million for the year ended December 31, 2024, as compared to a net loss of $28.2 million for the year ended December 31, 2023, an increase of $225.9 million. The increase was primarily due to the increase in operating income, lower interest expense, a reduced loss on the extinguishment of debt and the income tax benefit as compared to fiscal 2023.

    Adjusted Net Income was $119.2 million for the year ended December 31, 2024, as compared to Adjusted Net Income of $0.7 million for the year ended December 31, 2023, an increase of $118.5 million.

    Adjusted EBITDA was $164.6 million for the year ended December 31, 2024 as compared to Adjusted EBITDA of $40.2 million for the year ended December 31, 2023, an improvement of $124.4 million. The increase is primarily due to the substantial increase in operating income.

    At December 31, 2024, ADMA had working capital of $275.9 million, primarily consisting of $170.2 million of inventory, cash and cash equivalents of $103.1 million and $50.0 million of accounts receivable, partially offset by current liabilities of $55.5 million, as compared to working capital at December 31, 2023 of $207.2 million, primarily consisting of $172.9 million of inventory, cash and cash equivalents of $51.4 million and accounts receivable of $27.4 million, partially offset by current liabilities of $49.8 million.

    Conference Call Information:

    To access the conference call, please dial (888) 596-4144 and refer to conference ID 5201334. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under "Events & Webcasts" in the investor section of the Company's website at https://ir.admabiologics.com/events-webcasts.

    About ADMA Biologics, Inc. (ADMA)

    ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products. ADMA's mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

    Use of Non-GAAP Financial Measures

    This press release includes certain non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). The Company believes Adjusted EBITDA and Adjusted Net Income are useful to investors in evaluating the Company's financial performance. The Company uses Adjusted EBITDA and Adjusted Net Income as key performance measures because we believe that they facilitate operating performance comparisons from period to period that exclude potential differences driven by the impact of variations of non-cash items such as depreciation and amortization, as well as, in the case of Adjusted EBITDA, stock-based compensation or certain non-recurring items, and in the case of Adjusted Net Income, certain non-recurring items. The Company believes that investors should have access to the same set of tools used by our management and board of directors to assess our operating performance. Adjusted EBITDA and Adjusted Net Income should not be considered as measures of financial performance under GAAP, and the items excluded from Adjusted EBITDA and Adjusted Net Income are significant components in understanding and assessing the Company's financial performance. Accordingly, these key business metrics have limitations as an analytical tool. They should not be considered as an alternative to net income/loss, cash flows from operations, or any other performance measures derived in accordance with GAAP and may be different from similarly titled non-GAAP measures used by other companies. Please refer to the tables below for the reconciliation of GAAP measures to these non-GAAP measures for applicable periods.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. ("we," "our" or the "Company"). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as "confident," "estimate," "project," "intend," "forecast," "target," "anticipate," "plan," "planning," "expect," "believe," "will," "is likely," "will likely," "position us," "should," "could," "would," "may," "potential," "opportunity" or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about the Company's financial performance; revenue, GAAP net income, Adjusted EBITDA, Adjusted Net Income and margins guidance in future periods and related timing in connection therewith; ASCENIV's total revenue share and growth; our balance sheet; the benefits of newly executed high-titer plasma supply agreements and impact on ASCENIV growth and financial performance; the status of the yield enhancement production process submission and the anticipated impact of potential FDA approval on production yields and financial targets and related timing; ASCENIV revenue share and growth; ability to deliver stockholder value; our intention to file a Form 12b-25 with the SEC and file the Form 10-K within the 15-day extension period provided by Rule 12b-25 under the Exchange Act; statements regarding SG-001 and revenue potential; and ASCENIV's intellectual property estate. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the SEC, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.

    (1)Adjusted EBITDA is a non-GAAP financial measure. For a reconciliation of Adjusted EBITDA to the most comparable GAAP measure, see the reconciliation included in the financial tables.
    (2)Adjusted Net Income is a non-GAAP financial measure. For a reconciliation of Adjusted Net Income to the most comparable GAAP measure, see the reconciliation included in the financial tables. All non-GAAP adjustments are presented pre-tax.
      

    INVESTOR RELATIONS CONTACT:

    Argot Partners | 212-600-1902 | [email protected]

     
     
    ADMA BIOLOGICS, INC. AND SUBSIDIARIES

    CONSOLIDATED BALANCE SHEETS


     
     December 31, December 31,
      2024   2023 
     (In thousands, except share data)
     (Unaudited)  
    ASSETS   
    Current assets:   
    Cash and cash equivalents$103,147  $51,352 
    Accounts receivable, net 49,999   27,421 
    Inventories 170,235   172,906 
    Prepaid expenses and other current assets 8,029   5,334 
    Total current assets 331,410   257,013 
    Property and equipment, net 54,707   53,835 
    Intangible assets, net 460   499 
    Goodwill 3,530   3,530 
    Deferred tax assets 84,280   - 
    Right-of-use assets 8,634   9,635 
    Deposits and other assets 5,657   4,670 
    TOTAL ASSETS$488,678  $329,182 
        
    LIABILITIES AND STOCKHOLDERS' EQUITY    
    Current liabilities:   
    Accounts payable$20,219  $15,660 
    Accrued expenses and other current liabilities 33,962   32,919 
    Current portion of deferred revenue 143   182 
    Current portion of lease obligations 1,218   1,045 
    Total current liabilities 55,542   49,806 
    Senior notes payable, net of discount 72,337   130,594 
    Deferred revenue, net of current portion 1,547   1,690 
    End of term fee 1,313   1,688 
    Lease obligations, net of current portion 8,561   9,779 
    Other non-current liabilities 360   419 
    TOTAL LIABILITIES 139,660   193,976 
        
    COMMITMENTS AND CONTINGENCIES   
        
    STOCKHOLDERS' EQUITY    
    Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding -   - 
    Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 236,620,545 and 226,063,032 shares issued and outstanding at December 31, 2024 and December 31, 2023 24   23 
    Additional paid-in capital 657,577   641,439 
    Accumulated deficit (308,583)  (506,256)
    TOTAL STOCKHOLDERS' EQUITY  349,018   135,206 
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $488,678  $329,182 
        



    ADMA BIOLOGICS, INC. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF OPERATIONS


     
     Three Months ended December 31, Year ended December 31,
      2024   2023   2024   2023 
     (In thousands, except share and per share data)
     (Unaudited)   (Unaudited)  
            
    REVENUES$117,549  $73,904  $426,454  $258,215 
    Cost of product revenue 54,216   42,817   206,901   169,273 
    Gross profit  63,333   31,087   219,553   88,942 
            
    OPERATING EXPENSES:       
    Research and development 391   445   1,813   3,300 
    Plasma center operating expenses 1,277   685   4,245   4,266 
    Amortization of intangible assets 25   187   388   724 
    Selling, general and administrative 23,317   15,535   74,124   59,020 
    Total operating expenses 25,010   16,852   80,570   67,310 
            
    INCOME (LOSS) FROM OPERATIONS 38,323   14,235   138,983   21,632 
            
    OTHER INCOME (EXPENSE):       
    Interest income 598   612   2,097   1,617 
    Interest expense (2,879)  (6,215)  (13,930)  (25,027)
    Loss on extinguishment of debt (1,243)  (26,174)  (1,243)  (26,174)
    Other expense (86)  (101)  (193)  (287)
    Other expense, net (3,610)  (31,878)  (13,269)  (49,871)
            
    INCOME (LOSS) BEFORE INCOME TAXES 34,713   (17,643)  125,714   (28,239)
            
    Provision for income taxes (77,183)  -   (71,959)  - 
            
    NET INCOME (LOSS)$111,896  $(17,643) $197,673  $(28,239)
            
    BASIC EARNINGS (LOSS) PER COMMON SHARE$0.47  $(0.08) $0.85  $(0.13)
    DILUTED EARNINGS (LOSS) PER COMMON SHARE$0.46  $(0.08) $0.81  $(0.13)
            
    WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:       
    Basic  236,433,759   225,968,387   233,084,236   223,977,315 
    Diluted 245,900,655   225,968,387   243,342,466   223,977,315 
            



    NON-GAAP RECONCILIATION

    RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA


     
     Three Months ended December 31, Year ended December 31,
      2024   2023   2024   2023 
     (In thousands)
     (Unaudited)   (Unaudited)  
    Net income (loss)$111,896  $(17,643) $197,673  $(28,239)
    Depreciation 1,919   1,921   7,657   7,608 
    Amortization 25   188   388   724 
    Income taxes (77,183)  -   (71,959)  - 
    Interest expense 2,879   6,215   13,930   25,027 
    EBITDA 39,536   (9,319)  147,689   5,120 
    Stock-based compensation 5,433   1,745   13,616   6,187 
    Loss on extinguishment of debt 1,243   26,174   1,243   26,174 
    IT systems disruption -   -   -   2,770 
    Yield enhancement 2,064   -   2,064   - 
    Adjusted EBITDA$48,276  $18,600  $164,612  $40,251 
            



    NON-GAAP RECONCILIATION

    RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED NET INCOME


     
     Three Months ended December 31, Year ended December 31,
      2024   2023   2024   2023 
     (In thousands)
     (Unaudited)   (Unaudited)  
    Net income (loss)$111,896  $(17,643) $197,673  $(28,239)
    Deferred income tax benefit$(84,280)  -   (84,280)  - 
    Loss on extinguishment of debt$1,243   26,174   1,243   26,174 
    IT systems disruption   -   -   2,770 
    Yield Enhancement, non-recurring expenses$2,064     2,064   
    Share-based compensation modifications$2,518     2,518   
    Adjusted Net Income$33,441  $8,531  $119,218  $705 
            


    Primary Logo

    Get the next $ADMA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADMA

    DatePrice TargetRatingAnalyst
    7/19/2023$5.00Strong Buy
    Raymond James
    10/13/2022$5.00Buy
    Mizuho
    11/11/2021$5.00Outperform → Strong Buy
    Raymond James
    11/9/2021$4.50Overweight
    Cantor Fitzgerald
    10/26/2021$6.00 → $5.00Outperform
    Raymond James
    8/12/2021$7.00 → $6.00Buy
    HC Wainwright & Co.
    7/6/2021$10.00 → $7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ADMA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

      1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of $47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net Income(3) of $33.3 Million, an 87% YoY Increase 1Q 2025 Total Cash and Receivables Grew to Approximately $171 Million FDA Approved Yield Enhancement Process Anticipated to Provide 20% Production Output Enhancement from Same Starting Plasma Volume, and Support Revenue Growth and Margin Expansion Opportunity FY 2025 and 2026 Total Revenue Guidance Increased to More than $500 Million and $625 Million, Respectively FY 2025 Adjusted Net In

      5/7/25 4:05:00 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

      RAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2025 financial results on May 7, 2025, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and uni

      4/30/25 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process

      Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA's Uniquely Efficient Internal R&D Engine, Spanning Production and Product Development Capabilities Anticipate Approximately 20% Production Output Enhancement from Same Starting Plasma Volume The 20% Yield Enhancement Will Benefit Both ASCENIV and BIVIGAM RAMSEY, N.J. and BOCA RATON, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing,

      4/28/25 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James resumed coverage on ADMA Biologics with a new price target

      Raymond James resumed coverage of ADMA Biologics with a rating of Strong Buy and set a new price target of $5.00

      7/19/23 9:02:26 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mizuho initiated coverage on ADMA Biologics with a new price target

      Mizuho initiated coverage of ADMA Biologics with a rating of Buy and set a new price target of $5.00

      10/13/22 7:18:25 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics upgraded by Raymond James with a new price target

      Raymond James upgraded ADMA Biologics from Outperform to Strong Buy and set a new price target of $5.00

      11/11/21 6:21:44 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Leadership Updates

    Live Leadership Updates

    See more
    • ADMA Biologics Set to Join S&P SmallCap 600 Index

      RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market. "ADMA's inclusion in the S&P SmallCap 600 index is a significant milestone for our company," Adam Grossman, President and Chief Executive Officer of ADMA. "We expect this inclusion will increase our visibility within the investment communit

      9/17/24 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D.

      RAMSEY, N.J. and BOCA RATON, Fla., Oct. 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors. Dr. Kwon is a highly accomplished corporate executive in the life sciences and biotechnology space. He brings over a decade of expertise in strategic advising, corporate finance and business development transactions to ADMA's Board. "Young is a recognized leader in the healthcare sector and his deep strategic and financial experience

      10/18/21 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Financials

    Live finance-specific insights

    See more
    • ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

      1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of $47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net Income(3) of $33.3 Million, an 87% YoY Increase 1Q 2025 Total Cash and Receivables Grew to Approximately $171 Million FDA Approved Yield Enhancement Process Anticipated to Provide 20% Production Output Enhancement from Same Starting Plasma Volume, and Support Revenue Growth and Margin Expansion Opportunity FY 2025 and 2026 Total Revenue Guidance Increased to More than $500 Million and $625 Million, Respectively FY 2025 Adjusted Net In

      5/7/25 4:05:00 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

      RAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2025 financial results on May 7, 2025, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and uni

      4/30/25 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1) of $164.6 Million, a 309% YoY Increase FY 2024 Adjusted Net Income(2) of $119.2 Million, Compared to $0.7 Million in FY 2023, a 16,810% YoY Increase YE 2024 Total Cash Grew to More than $103 Million, Including $60 Million of Debt Organically Discharged During 2H 2024 High-Titer Plasma Supply Contracts Expected to Provide Foundation for Durable ASCENIV Revenue Growth Through Late 2030s FDA Approval of Yield Enhancement Production Process Anticipated by Mid-2025

      3/3/25 4:05:00 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by ADMA Biologics Inc

      SCHEDULE 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

      5/9/25 4:14:39 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by ADMA Biologics Inc

      10-Q - ADMA BIOLOGICS, INC. (0001368514) (Filer)

      5/7/25 5:15:53 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)

      5/7/25 4:12:24 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Grossman Adam S exercised 15,000 shares at a strike of $5.40 and sold $450,660 worth of shares (21,000 units at $21.46), decreasing direct ownership by 0.29% to 2,055,850 units (SEC Form 4)

      4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

      4/16/25 9:00:26 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • COO and SVP, Compliance Kestenberg-Messina Kaitlin M. covered exercise/tax liability with 18,920 shares, decreasing direct ownership by 4% to 490,425 units (SEC Form 4)

      4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

      4/2/25 9:00:38 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Grossman Adam S exercised 15,000 shares at a strike of $5.40 and sold $397,320 worth of shares (21,000 units at $18.92), decreasing direct ownership by 0.29% to 2,061,850 units (SEC Form 4)

      4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

      3/21/25 9:00:15 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ADMA Biologics Inc

      SC 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)

      11/12/24 1:34:17 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by ADMA Biologics Inc

      SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

      11/8/24 9:21:37 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by ADMA Biologics Inc

      SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

      11/4/24 11:00:41 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care